ERAS Erasca, Inc.
ERAS Erasca, Inc.
Healthcare · Biotechnology
Market read
Scan convergence 1 scan as of 2026-08-17 1 bull converging
POC $10.41 · VWAP $11.81 · +54.8% vs 12m avg buyer
Insiders no data — outside the Form 4 poll — US-filer feed only (foreign filers report via MAR managers'-transactions notices)
Coverage
1 watchlist
ERAS Price Structure
Loading timeframes…
Peers
Every watchlist ERAS belongs to, members best 30-day change first — ERAS highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@monster-discoveries
Reported EPS $-0.14 versus analyst consensus of $-0.11 (-25.1%).
full note →Against street estimates
How ERAS's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
News (last pull)
Headlines about ERAS from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 58 days ago · Jun 21
- Erasca, Inc. (ERAS) Shares Crater 48%, Wiping Out $2.8 Billion of Market Cap; HBSS Investigating Intellectual Property Questions Regarding Lead Asset
- Erasca Reports First Quarter 2026 Business Updates and Financial Results
- Erasca enters AURORAS-1 clinical trial pact, supply agreement with Merck
- Erasca recent share selloff overdone, says JPMorgan
- Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results
ERAS research tape
37 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.